← Markets

Nuvation Bio Inc.

NUVB · NYSE

Market closed$5.80$0.160000 (+2.84%)After hours $5.83 · +0.52%

Key statistics

Previous close$5.64
Open$5.41
Day high$5.85
Day low$5.34
52-week high$9.75
52-week low$2.18
Market cap2.01B
Volume3.32M
Average volume6.07M
P/E ratio-13.49
Forward P/E—
EPS-0.43
Dividend yield0.00%

Market context

Why it moved

Nuvation Bio's stock moved higher as positive sentiment built around the company's growing oncology pipeline, highlighted by its FDA-approved Ibtrozi and a recent UK marketing application acceptance for taletrectinib, reinforcing investor confidence in the biotech's commercial trajectory.

InstagramInvesting.comYelpAaStocktitan

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Nuvation Bio gained nearly 3%, buoyed by a confluence of company-specific catalysts and a broadly supportive biopharma backdrop. The oncology-focused biotech continues to build momentum following its June 2025 FDA approval of Ibtrozi (taletrectinib) for ROS1-positive NSCLC and a recent UK marketing application acceptance, while a licensing deal with Daiichi Sankyo for safusidenib rights in Japan signals growing global commercial ambitions. RBC Capital reaffirmed its Outperform rating ahead of Q2 earnings, though it trimmed its price target to $19 from $20, still implying substantial upside from current levels near $5.80.

2.8369

July 17, 2026Nuvation Bio fell over 4% as investors digested a modest RBC Capital price target trim to $19 from $20 (Outperform maintained) ahead of Q2 earnings, even as the company's pipeline momentum remains a key focus. The oncology biotech recently secured UK MHRA acceptance of its taletrectinib marketing application for ROS1-positive NSCLC — adding to existing approvals in the US, Japan, and China — while analysts see more than 150% upside and a fair value near $12. Broader healthcare sector pressure weighed as well, with XLV also declining on the day.

-4.4068

July 14, 2026Nuvation Bio edged lower as broader markets declined amid renewed U.S.-Iran tensions, though company-specific momentum remains constructive: the UK's MHRA validated Eisai's Marketing Authorisation Application for taletrectinib in advanced ROS1-positive NSCLC, extending the drug's international regulatory footprint after prior approvals in the U.S., Japan, and China. Royal Bank of Canada maintained an Outperform rating on NUVB but trimmed its price target to $19 from $20, while some analysts see ~75% upside based on a $10.25 fair value estimate, and billionaire investor David Abrams continues to hold NUVB as a top pick amid a broader biotech rally.

-0.6885

July 11, 2026Nuvation Bio fell nearly 5% amid a broader pullback in small-cap biotech names, even as the S&P 500 edged modestly higher on AI-driven momentum. The decline came despite a constructive analyst backdrop: RBC Capital and Truist Securities both reiterated bullish ratings on July 7, with Truist raising its price target to $13 and RBC maintaining an Outperform with a $19 target. Investor attention remains on taletrectinib's expanding global footprint, including the UK MHRA's recent validation of Eisai's Marketing Authorisation Application, building on approvals in the U.S., Japan, and China.

-4.91

July 10, 2026Nuvation Bio surged on above-average volume, outperforming the broader healthcare sector (XLV essentially flat) amid a confluence of positive catalysts. Truist Securities raised its price target to $13 from $12 while maintaining a Buy rating, and the UK's MHRA validated partner Eisai's Marketing Authorisation Application for taletrectinib in ROS1-positive non-small cell lung cancer, expanding the therapy's international regulatory footprint. The stock continues to benefit from broader biotech sector tailwinds, with Jim Cramer recently calling biotech "the hottest group in the market" and predicting an M&A wave, while the company's recently closed $287.5M convertible notes offering strengthens its balance sheet to advance its oncology pipeline.

4.0886

July 8, 2026Nuvation Bio closed modestly higher amid a flurry of positive catalysts, with the healthcare sector outperforming broader markets for a second consecutive week. The company completed its $287.5M convertible notes offering after underwriters fully exercised the greenshoe option, bolstering its balance sheet with ~$277.6M in net proceeds to fund its oncology pipeline. Multiple analyst upgrades added to the bullish tone: Truist Securities raised its price target to $13 (from $12) while maintaining Buy, and RBC Capital reiterated Outperform, highlighting the value of Nuvation's ROS1 franchise following GSK's acquisition of competitor Nuvularia. The UK MHRA's validation of a Marketing Authorization Application for taletrectinib in ROS1-positive NSCLC further supports the pipeline narrative.

1.25

July 7, 2026Nuvation Bio closed modestly lower as investors weighed the full exercise of underwriters' greenshoe option in its $287.5 million convertible senior notes offering, which closed June 30, 2026 — a move that signals strong institutional demand but also raises dilution concerns. Separately, the UK MHRA's validation of partner Eisai's marketing application for taletrectinib (IBTROZI) in ROS1-positive non-small cell lung cancer adds a key regulatory milestone, with analysts flagging the stock as potentially 71% undervalued relative to a $19.70 fair value estimate.

-1.7544

July 3, 2026Nuvation Bio surged on continued momentum from a confluence of catalysts: the U.K. MHRA validation of partner Eisai's Marketing Authorisation Application for taletrectinib in ROS1-positive non-small cell lung cancer, a Wedbush note highlighting more predictable growth supported by IBTROZI frontline adoption, and the completion of a $250 million convertible notes offering that retired secured debt and strengthened the balance sheet. Healthcare was the top-performing S&P sector on the day amid a soft U.S. jobs report that eased rate-hike fears, providing a favorable backdrop for biotech names.

5.1661

Stock Titan · May 5, 2026Nuvation Bio's CEO and CFO line up four investor webcasts in MayPR Newswire · May 4, 2026Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business UpdateInvesting News Network · April 1, 2026Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi SankyoInvesting.com · March 3, 2026Citizens reiterates Nuvation Bio stock rating on Ibtrozi launchPR Newswire · March 2, 2026Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateBusiness Wire · January 12, 2026Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference
Benzinga · July 7, 2026RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $19
Benzinga · July 7, 2026Truist Securities Maintains Buy on Nuvation Bio, Raises Price Target to $13
Mt Newswire · July 7, 2026RBC Capital Adjusts Nuvation Bio Price Target to $19 From $20, Maintains Outperform Rating
Mt Newswire · June 30, 2026Nuvation Bio Faces More Predictable Growth Supported by Ibtrozi Frontline Adoption, Wedbush Says
Mt Newswire · June 29, 2026Nuvation Bio's Taletrectinib Enters UK Regulatory Review
Mt Newswire · June 26, 2026Nuvation Bio Prices $250 Million Convertible Bond Offering
Mt Newswire · June 25, 2026Nuvation Bio to Launch $200 Million Senior Notes Offering; Shares Fall Pre-Bell
Benzinga · June 25, 2026Nuvation Bio Intends To Offer $200M Aggregate Principal Amount Of Convertible Senior Notes Due In 2032

Peers

S&P 500SPX · $7,457.69-1.01%Vertex Pharmaceuticals IncorporatedVRTX · $485.65-0.08%Regeneron Pharmaceuticals, Inc.REGN · $676.69-0.33%Alnylam Pharmaceuticals, Inc.ALNY · $267.47-5.54%argenx SEARGX · $860.55+0.30%BioNTech SEBNTX · $91.48-0.09%Incyte CorporationINCY · $117.25+0.51%BridgeBio Pharma, Inc.BBIO · $81.38+1.34%Rhythm Pharmaceuticals, Inc.RYTM · $106.60+0.48%Mirum Pharmaceuticals, Inc.MIRM · $118.86+1.28%Spyre Therapeutics, Inc.SYRE · $100.23+6.49%Bristol-Myers Squibb CompanyBMY · $60.74+0.38%